Last updated on August 2016

Inovio TRT-001: Telomerase DNA Immunotherapy in Breast Lung and Pancreatic Cancers


Brief description of study

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.

Clinical Study Identifier: NCT02327468

Find a site near you

Start Over